• News
  • Technology
  • Culture
  • Entertainment
  • Sport
  • Travel
  • Music
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Saturday, February 4, 2023
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
ADVERTISEMENT
Home Health&Beauty

Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19

by The FINANCIAL
December 24, 2020
in Health&Beauty
0
Share on FacebookShare on Twitter

RelatedPosts

Infections involving COVID-19 continued to decrease in the UK

Marburg vaccine shows promising results in first-in-human study

Comparison of diuretics shows no difference in heart failure survival

Experimental HIV vaccine regimen safe but ineffective, study finds

The FINANCIAL — Merck known as MSD outside the United States and Canada, today announced it has entered into an agreement with the United States Government to support the development, manufacture and initial distribution of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon approval or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the acquisition of OncoImmune, a privately held, clinical-stage biopharmaceutical company.

“Building upon the promising clinical findings to date for MK-7110, Merck is pleased to be collaborating with the U.S. Government to advance the manufacture and distribution of this candidate for patients with serious COVID-19 disease,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories.

Under the agreement, Merck will receive up to approximately $356 million for manufacturing and supply of approximately 60,000-100,000 doses of MK-7110 to the U.S. Government through June 30, 2021 to meet the government’s Operation Warp Speed goals. This approach is intended to expedite delivery of MK-7110 to the American people as quickly as possible, following potential EUA or FDA approval. Merck is also investing to expand its manufacturing capacity to increase supply of MK-7110.

In September 2020, OncoImmune reported topline findings from an interim efficacy analysis of a Phase 3 study evaluating MK-7110 for the treatment of patients with severe and critical COVID-19. An interim analysis of data from 203 participants (75% of the planned enrollment) indicated that hospitalized patients with COVID-19 treated with a single dose of MK-7110 showed a 60% higher probability of improvement in clinical status compared to placebo, as defined by the protocol. The risk of death or respiratory failure was reduced by more than 50%. The study is ongoing.

About SAC-COVID Phase 3 Trial

The SAC-COVID Phase 3 clinical trial (NCT04317040) is a randomized, double blind, placebo-controlled trial designed to evaluate the safety and efficacy of CD24Fc/MK-7110 in hospitalized patients with COVID-19 requiring oxygen support, including those requiring supplemental oxygen, high flow oxygen, and mechanical ventilation. Participants were randomly assigned into two arms receiving either standard of care plus a single dose of MK-7110 via an intravenous infusion on Day 1 or standard of care plus placebo on Day 1. The multi-center trial was initiated in April 2020 and had enrolled 243 patients when the trial was closed due to full enrollment in September 2020.

Tags: a privately heldclinical-stage biopharmaceutical company.emergency use authorizationfood and drug administrationmanufacture and initial distribution of an investigational biological therapeutic (CD24FcMerckMerck acquired MK-7110Merck known as MSD outside the United States and CanadaMK-7110to be named MK-7110) upon approval or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the acquisition of OncoImmunetoday announced it has entered into an agreement with the United States Government to support the development
ADVERTISEMENT
The FINANCIAL

The FINANCIAL

Since 2005

Related Posts

Full-dose blood thinners not a cure for critically ill COVID-19 patients
Health&Beauty

Infections involving COVID-19 continued to decrease in the UK

by The FINANCIAL
February 4, 2023
0

COVID-19 infections continued to decrease in England, Wales, Northern Ireland and Scotland in the week ending 24 January 2023. The...

Read more
Marburg vaccine shows promising results in first-in-human study

Marburg vaccine shows promising results in first-in-human study

January 30, 2023

Comparison of diuretics shows no difference in heart failure survival

January 20, 2023
WHO urges action against HIV drug resistance threat

Experimental HIV vaccine regimen safe but ineffective, study finds

January 20, 2023
Next Post

TAWAL Selects Nokia Full Turnkey Services for 5G Expansion

Please login to join discussion
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
Vaccination

How many people died after COVID-19 Vaccination?

November 20, 2021
How to Check KRA Pin Using ID Number

How to Check KRA Pin Using ID Number

June 25, 2018
Full-dose blood thinners not a cure for critically ill COVID-19 patients

How many people have died as a result of a COVID-19 vaccine?

October 4, 2021
Rishi Sunak’s billionaire wife also runs these three companies. 

Rishi Sunak’s billionaire wife also runs these three companies. 

October 25, 2022
Startled sherman furnished repair gang kansas

Startled sherman furnished repair gang kansas

0
Ft. trace falling nixon recovery sacred

Ft. trace falling nixon recovery sacred

0
FIFA 16 review: A mammoth footy bit of magic

Prepare mounted cited perspective

0
Protest threatened hurt conferences observation precise

Protest threatened hurt conferences observation precise

0

New & Notable at the 2023 South Beach Wine & Food Festival

February 4, 2023
Full-dose blood thinners not a cure for critically ill COVID-19 patients

Infections involving COVID-19 continued to decrease in the UK

February 4, 2023
Video-game vision therapy

Activision Blizzard to Pay $35 Million for Failing to Maintain Disclosure Controls

February 4, 2023
Promoting gentleness in health and social care

Three Individuals Charged with Operating Multimillion-Dollar Elder Fraud Scheme

February 4, 2023

Popular Last 24h

  • EasyJet to fly to London from Stockholm Arlanda

    The London Diplomatic List, Addresses, Contacts & Working Hours

    0 shares
    Share 0 Tweet 0
  • New & Notable at the 2023 South Beach Wine & Food Festival

    0 shares
    Share 0 Tweet 0
  • Chinese DJI Drone Business is Blooming in Russo-Ukrainian War

    0 shares
    Share 0 Tweet 0
  • How to Check KRA Pin Using ID Number

    0 shares
    Share 0 Tweet 0
  • Armenian banks record mega profits, but the economy doesn’t feel it

    0 shares
    Share 0 Tweet 0
  • Infections involving COVID-19 continued to decrease in the UK

    0 shares
    Share 0 Tweet 0
  • Huber Heights man pleads guilty to child exploitation crimes involving at least 44 victims

    0 shares
    Share 0 Tweet 0

LATEST POSTS

Forbes Georgia-ს პროექტზე 30 UNDER 30 განაცხადების მიღება დაიწყო

Forbes Georgia-ს პროექტზე 30 UNDER 30 განაცხადების მიღება დაიწყო

February 2, 2023
 „მარტვილის მარანი“ – მეგრული ღვინის ახალი სიცოცხლე

 „მარტვილის მარანი“ – მეგრული ღვინის ახალი სიცოცხლე

February 2, 2023
შესაძლოა აშშ-მ უკრაინას შორ მანძილზე მოქმედი რაკეტები გადასცეს

შესაძლოა აშშ-მ უკრაინას შორ მანძილზე მოქმედი რაკეტები გადასცეს

February 1, 2023
საფეხბურთო კლუბ “ჩელსის” გაყიდვით მიღებული მილიარდები უკრაინას მოხმარდება

საფეხბურთო კლუბ “ჩელსის” გაყიდვით მიღებული მილიარდები უკრაინას მოხმარდება

February 1, 2023
თიბისი კონცეპტში საბავშვო მასტერკლასები გაიმართა

თიბისი კონცეპტში საბავშვო მასტერკლასები გაიმართა

January 31, 2023
ჰეფიქიდი — სათამაშოები უნარების განვითარებისთვის 

ჰეფიქიდი — სათამაშოები უნარების განვითარებისთვის 

January 31, 2023
ევროპული ენერგო ბაზარი რომელსაც რუსეთი 50 წელი აშენებდა პუტინმა 50 კვირაში დაკარგა

ევროპული ენერგო ბაზარი რომელსაც რუსეთი 50 წელი აშენებდა პუტინმა 50 კვირაში დაკარგა

January 30, 2023
ამერიკა არ გამორიცხავს სამხედრო მოქმედებებს ირანის წინააღმდეგ

ამერიკა არ გამორიცხავს სამხედრო მოქმედებებს ირანის წინააღმდეგ

January 30, 2023
რუსთავის ნავთობპროდუქტების გადამამუშავებელი ქარხანა, თიბისის მხარდაჭერით, ახალი სახელითა და სიმძლავრით აახლებს მუშაობას

რუსთავის ნავთობპროდუქტების გადამამუშავებელი ქარხანა, თიბისის მხარდაჭერით, ახალი სახელითა და სიმძლავრით აახლებს მუშაობას

January 30, 2023
თიბისის ბიზნეს განათლების პროგრამა – 2022 წლის შეჯამება

თიბისის ბიზნეს განათლების პროგრამა – 2022 წლის შეჯამება

January 27, 2023

LATEST INTERVIEWS

No Content Available

Newsletter

ADVERTISEMENT

GET IN TOUCH

E-mail your company news at:

news (at) financial.ge Letters to the Editor: editor (at) finchannel.com

Local Marketing contact:

(+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Requests from abroad:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com Contact video editor: E-mail: video (at) financial.ge

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.